Journal article
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation
Abstract
The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for stroke prevention in many patients with nonvalvular atrial fibrillation. Edoxaban, an oral factor Xa inhibitor, is the newest entrant in this class. Results of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE AF) study demonstrate that edoxaban is noninferior to warfarin for prevention of stroke and systemic embolic …
Authors
Weitz JI; Eikelboom J
Journal
Thrombosis and Haemostasis, Vol. 115, No. 02, pp. 257–270
Publisher
Thieme
Publication Date
3 2016
DOI
10.1160/th15-02-0181
ISSN
0340-6245